Methylation of tumour suppressor genes APAF-1 and DAPK-1 and in vitro effects of demethylating agents in bladder and kidney cancer

British Journal of Cancer

Volumn 95, Issue 12, 2006, Pages 1701-1707

  Christoph, F ^a   Kempkensteffen, C ^a   Weikert, S ^a   Kollermann J ^b   Krause, H ^a   Miller, K ^a   Schostak, M ^a   Schrader, M ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

5 aza 2 deoxycytidine; Hypermethylation; p53 mutation; p53 target gene; Zebularine

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; DEATH ASSOCIATED PROTEIN KINASE; MESSENGER RNA; PROTEIN P53; ZEBULARINE;

ARTICLE; BLADDER; BLADDER CARCINOMA; CANCER GROWTH; CANCER INHIBITION; CANCER SIZE; CONTROLLED STUDY; DNA METHYLATION; DRUG EFFECT; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENETIC TRANSCRIPTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; KIDNEY PARENCHYMA; MALE; MICRODISSECTION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSITIONAL CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS REGULATORY PROTEINS; APOPTOTIC PROTEASE-ACTIVATING FACTOR 1; AZACITIDINE; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CARCINOMA, RENAL CELL; CARCINOMA, TRANSITIONAL CELL; CELLS, CULTURED; CYTIDINE; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY; KIDNEY NEOPLASMS; MALE; PROMOTER REGIONS (GENETICS); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 33845624653     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603482     Document Type: Article

References (37)

1. Amato RJ (2000) Chemotherapy for renal cell carcinoma. Semin Oncol 27: 177-186
2. Bender CM, Pao MM, Jones PA (1998) Inhibition of DNA methylation by 5-aza-20-deoxycytidine suppresses the growth of human tumor cell lines. Cancer Res 58: 95-101
3. Ben-Kasus T, Ben-Zvi Z, Marquez VE, Kelley JA, Agbaria R (2005) Metabolic activation of zebularine, a novel DNA methylation inhibitor, in human bladder carcinoma cells. Biochem Pharmacol 70: 121-133
4. Boyle P, Ferlay J (2005) Cancer incidence and mortality in Europe, 2004. Ann Oncol 16: 481-488
5. Breault JE, Shiina H, Igawa M, Ribeiro-Filho LA, Deguchi M, Enokida H, Urakami S, Terashima M, Nakagawa M, Kane CJ, Carroll PR, Dahiya R (2005) Methylation of the gamma-catenin gene is associated with poor prognosis of renal cell carcinoma. Clin Cancer Res 11: 557-564
6. Catto JW, Azzouzi AR, Rehman I, Feeley KM, Cross SS, Amira N, Fromont G, Sibony M, Cussenot O, Meuth M, Hamdy FC (2005) Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J Clin Oncol 23: 2903-2910
7. Chan AW, Chan MW, Lee TL, Ng EK, Leung WK, Lau JY, Tong JH, Chan FK, To KF (2005) Promoter hypermethylation of death-associated protein-kinase gene associated with advance stage gastric cancer. Oncol Rep 13: 937-941
8. Cheng JC, Matsen CB, Gonzales FA, Ye W, Greer S, Marquez VE, Jones PA, Selker EU (2003) Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst 95: 399-409
9. Cheng JC, Weisenberger DJ, Gonzales FA, Liang G, Xu GL, Hu YG, Marquez VE, Jones PA (2004a) Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells. Mol Cell Biol 24: 1270-1278
10. Cheng JC, Yoo CB, Weisenberger DJ, Chuang J, Wozniak C, Liang G, Marquez V, Greer S, Orntoft T, Thykjaer T, Jones PA (2004b) Preferential response of cancer cells to zebularine. Cancer Cell 6: 151-158
11. Dulaimi E, De II C, Uzzo RG, Al-Saleem T, Greenberg RE, Polascik TJ, Babb JS, Grizzle WE, Cairns P (2004) Promoter hypermethylation profile of kidney cancer. Clin Cancer Res 10: 3972-3979
12. Feinstein E, Druck T, Kastury K, Berissi H, Goodart SA, Overhauser J, Kimchi A, Huebner K (1995) Assignment of DAP1 and DAPK-genes that positively mediate programmed cell death triggered by IFN-gamma-to chromosome regions 5p12.2 and 9q34.1, respectively. Genomics 29: 305-307
13. Friedrich MG, Weisenberger DJ, Cheng JC, Chandrasoma S, Siegmund KD, Gonzalgo ML, Toma MI, Huland H, Yoo C, Tsai YC, Nichols PW, Bochner BH, Jones PA, Liang G (2004) Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients. Clin Cancer Res 10: 7457-7465
14. Fu WN, Bertoni F, Kelsey SM, McElwaine SM, Cotter FE, Newland AC, Jia L (2003) Role of DNA methylation in the suppression of Apaf-1 protein in human leukaemia. Oncogene 22: 451-455
15. Garcia JA, Dreicer R (2005) Adjuvant and neoadjuvant chemotherapy for bladder cancer: management and controversies. Nat Clin Pract Urol 2: 32-37
16. Giard DJ, Aaronson SA, Todaro GJ, Arnstein P, Kersey JH, Dosik H, Parks WP (1973) In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst 51: 1417-1423
17. Gonzalgo ML, Yegnasubramanian S, Yan G, Rogers CG, Nicol TL, Nelson WG, Pavlovich CP (2004) Molecular profiling and classification of sporadic renal cell carcinoma by quantitative methylation analysis. Clin Cancer Res 21: 7276-7283
18. Herranz M, Martin-Caballero J, Fraga MF, Ruiz-Cabello J, Flores JM, Desco M, Marquez V, Esteller M (2006) The novel DNA methylation inhibitor zebularine is effective against the development of murine T-cell lymphoma. Blood 107: 1174-1177
19. Jeronimo C, Usadel H, Henrique R, Oliveira J, Lopes C, Nelson WG, Sidransky D (2001) Quantitation of GSTP1 methylation in nonneoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J Natl Cancer Inst 93: 1747-1752
20. Jia L, Srinivasula SM, Liu FT, Newland AC, Fernandes-Alnemri T, Alnemri ES, Kelsey SM (2001) Apaf-1 protein deficiency confers resistance to cytochrome c-dependent apoptosis in human leukemic cells. Blood 98: 414-421
21. Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428
22. Karge III WH, Schaefer EJ, Ordovas JM (1998) Quantification of mRNA by polymerase chain reaction (PCR) using an internal standard and a nonradioactive detection method. Methods Mol Biol 110: 43-61
23. Kim CH, Marquez VE, Mao DT, Haines DR, McCormack JJ (1986) Synthesis of pyrimidin-2-one nucleosides as acid-stable inhibitors of cytidine deaminase. J Med Chem 29: 1374-1380
24. Kim DH, Nelson HH, Wiencke JK, Christiani DC, Wain JC, Mark EJ, Kelsey KT (2001) Promoter methylation of DAP-kinase: association with advanced stage in non-small cell lung cancer. Oncogene 20: 1765-1770
25. Kissil JL, Feinstein E, Cohen O, Jones PA, Tsai YC, Knowles MA, Eydmann ME, Kimchi A (1997) DAP-kinase loss of expression in various carcinoma and B-cell lymphoma cell lines: possible implications for role as tumor suppressor gene. Oncogene 15: 403-407
26. Kraemer K, Fuessel S, Schmidt U, Kotzsch M, Schwenzer B, Wirth MP, Meye A (2003) Antisense-mediated hTERT inhibition specifically reduces the growth of human bladder cancer cells. Clin Cancer Res 9: 3794-3800
27. Levine AJ, Momand J, Finlay CA (1991) The p53 tumour suppressor gene. Nature 351: 453-456
28. Marquez VE, Barchi Jr JJ, Kelley JA, Rao KV, Agbaria R, Ben-Kasus T, Cheng JC, Yoo CB, Jones PA (2005) Zebularine: a unique molecule for an epigenetically based strategy in cancer chemotherapy. The magic of its chemistry and biology. Nucleosides Nucleotides Nucleic Acids 24: 305-318
29. Momparler RL (1985) Molecular, cellular and animal pharmacology of 5-aza-20-deoxycytidine. Pharmacol Ther 30: 287-299
30. Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST, Baum CM, Michaelson MD (2006) Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295: 2516-2524
31. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, Gore M, Desai AA, Patnaik A, Xiong HQ, Rowinsky E, Abbruzzese JL, Xia C, Simantov R, Schwartz B, O'Dwyer PJ (2006) Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24: 2505-2512
32. Rigby CC, Frankis LM (1970) A human tissue culture cell line from a transitional cell tumour of the urinary bladder: growth, chromosone pattern and ultrastructure. Br J Cancer 24: 746-754
33. Sanchez-Cespedes M, Esteller M, Wu L, Nawroz-Danish H, Yoo GH, Koch WM, Jen J, Herman JG, Sidransky D (2000) Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res 60: 892-895
34. Soengas MS, Capodieci P, Polsky D, Mora J, Esteller M, Opitz-Araya X, McCombie R, Herman JG, Gerald WL, Lazebnik YA, Cordon-Cardo C, Lowe SW (2001) Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 409: 207-211
35. Tada Y, Wada M, Taguchi K, Mochida Y, Kinugawa N, Tsuneyoshi M, Naito S, Kuwano M (2002) The association of death-associated protein kinase hypermethylation with early recurrence in superficial bladder cancers. Cancer Res 62: 4048-4053
36. Tang X, Wu W, Sun SY, Wistuba II, Hong WK, Mao L (2004) Hypermethylation of the death-associated protein kinase promoter attenuates the sensitivity to TRAIL-induced apoptosis in human nonsmall cell lung cancer cells. Mol Cancer Res 2: 685-691
37. Wethkamp N, Ramp U, Geddert H, Schulz WA, Florl AR, Suschek CV, Hassan M, Gabbert HE, Mahotka C (2006) Expression of death-associated protein kinase during tumour progression of human renal cell carcinomas: hypermethylation- independent mechanisms of inactivation. Eur J Cancer 42: 264-274